Raleigh Capital Management Inc. Sells 6,614 Shares of Gilead Sciences, Inc. $GILD

Raleigh Capital Management Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 76.6% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,026 shares of the biopharmaceutical company’s stock after selling 6,614 shares during the quarter. Raleigh Capital Management Inc.’s holdings in Gilead Sciences were worth $282,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Paulson Wealth Management Inc. increased its holdings in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 67 shares during the period. Essex Financial Services Inc. boosted its holdings in Gilead Sciences by 0.9% during the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after acquiring an additional 71 shares during the period. Davidson Trust Co. boosted its holdings in Gilead Sciences by 4.1% during the 1st quarter. Davidson Trust Co. now owns 1,879 shares of the biopharmaceutical company’s stock valued at $262,000 after acquiring an additional 74 shares during the period. Alpha Cubed Investments LLC grew its position in Gilead Sciences by 1.1% during the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after acquiring an additional 75 shares during the last quarter. Finally, Personal CFO Solutions LLC grew its position in Gilead Sciences by 1.7% during the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 76 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $131.27 on Monday. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences, Inc. has a 12-month low of $107.75 and a 12-month high of $157.29. The company has a market cap of $162.98 billion, a P/E ratio of 17.88 and a beta of 0.32. The company’s fifty day simple moving average is $129.44 and its two-hundred day simple moving average is $134.64.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same period last year, the business posted $1.81 earnings per share. Gilead Sciences’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post -0.8 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on GILD. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Weiss Ratings downgraded shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, May 28th. Morgan Stanley lowered their price target on shares of Gilead Sciences from $175.00 to $168.00 in a report on Friday, May 8th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Finally, Truist Financial reaffirmed a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research note on Friday, May 8th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $159.22.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $123.92, for a total transaction of $371,760.00. Following the sale, the insider owned 124,234 shares of the company’s stock, valued at $15,395,077.28. This trade represents a 2.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,000 shares of company stock valued at $10,824,500 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.